Research ExplorerPublicationsStatement by the Kommission OVAR of the AGO Study Group on t...

Statement by the Kommission OVAR of the AGO Study Group on the Use of HIPEC (Hyperthermic Intraperitoneal Chemotherapy) to Treat Primary and Recurrent Ovarian Cancer

Standard

Statement by the Kommission OVAR of the AGO Study Group on the Use of HIPEC (Hyperthermic Intraperitoneal Chemotherapy) to Treat Primary and Recurrent Ovarian Cancer. / Harter, P; Mahner, S; Hilpert, F; Runnebaum, I; Ortmann, O; Mustea, A; Sehouli, J; du Bois, A; Wagner, U; Kommission Ovar of the Arbeitsgemeinschaft Gynäkologische Onkologie.

In: GEBURTSH FRAUENHEILK, Vol. 73, No. 3, 01.03.2013, p. 221-223.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Harter, P, Mahner, S, Hilpert, F, Runnebaum, I, Ortmann, O, Mustea, A, Sehouli, J, du Bois, A, Wagner, U & Kommission Ovar of the Arbeitsgemeinschaft Gynäkologische Onkologie 2013, 'Statement by the Kommission OVAR of the AGO Study Group on the Use of HIPEC (Hyperthermic Intraperitoneal Chemotherapy) to Treat Primary and Recurrent Ovarian Cancer', GEBURTSH FRAUENHEILK, vol. 73, no. 3, pp. 221-223. https://doi.org/10.1055/s-0032-1328320

APA

Harter, P., Mahner, S., Hilpert, F., Runnebaum, I., Ortmann, O., Mustea, A., Sehouli, J., du Bois, A., Wagner, U., & Kommission Ovar of the Arbeitsgemeinschaft Gynäkologische Onkologie (2013). Statement by the Kommission OVAR of the AGO Study Group on the Use of HIPEC (Hyperthermic Intraperitoneal Chemotherapy) to Treat Primary and Recurrent Ovarian Cancer. GEBURTSH FRAUENHEILK, 73(3), 221-223. https://doi.org/10.1055/s-0032-1328320

Vancouver

Harter P, Mahner S, Hilpert F, Runnebaum I, Ortmann O, Mustea A et al. Statement by the Kommission OVAR of the AGO Study Group on the Use of HIPEC (Hyperthermic Intraperitoneal Chemotherapy) to Treat Primary and Recurrent Ovarian Cancer. GEBURTSH FRAUENHEILK. 2013 Mar 1;73(3):221-223. https://doi.org/10.1055/s-0032-1328320

Bibtex

@article{55d07bba98954c9cbec621c2126975ba,
title = "Statement by the Kommission OVAR of the AGO Study Group on the Use of HIPEC (Hyperthermic Intraperitoneal Chemotherapy) to Treat Primary and Recurrent Ovarian Cancer",
abstract = "HIPEC is offered to patients with ovarian, fallopian tube or primary peritoneal cancer at some hospitals. Altogether, there is still no evidence that HIPEC leads to an improvement of prognosis in any gynecologic tumor, neither in primary therapy nor in treatment of relapse. The available data indicate an increased complication rate which might negatively impact the benefit-risk balance of this procedure. In addition, standard treatment with proven efficacy might be withheld due to application of unproven methods. The use of HIPEC outside of well designed, prospective and controlled clinical trials is therefore disregarded.",
author = "P Harter and S Mahner and F Hilpert and I Runnebaum and O Ortmann and A Mustea and J Sehouli and {du Bois}, A and U Wagner and {Kommission Ovar of the Arbeitsgemeinschaft Gyn{\"a}kologische Onkologie}",
year = "2013",
month = mar,
day = "1",
doi = "10.1055/s-0032-1328320",
language = "English",
volume = "73",
pages = "221--223",
journal = "GEBURTSH FRAUENHEILK",
issn = "0016-5751",
publisher = "Georg Thieme Verlag KG",
number = "3",

}

RIS

TY - JOUR

T1 - Statement by the Kommission OVAR of the AGO Study Group on the Use of HIPEC (Hyperthermic Intraperitoneal Chemotherapy) to Treat Primary and Recurrent Ovarian Cancer

AU - Harter, P

AU - Mahner, S

AU - Hilpert, F

AU - Runnebaum, I

AU - Ortmann, O

AU - Mustea, A

AU - Sehouli, J

AU - du Bois, A

AU - Wagner, U

AU - Kommission Ovar of the Arbeitsgemeinschaft Gynäkologische Onkologie

PY - 2013/3/1

Y1 - 2013/3/1

N2 - HIPEC is offered to patients with ovarian, fallopian tube or primary peritoneal cancer at some hospitals. Altogether, there is still no evidence that HIPEC leads to an improvement of prognosis in any gynecologic tumor, neither in primary therapy nor in treatment of relapse. The available data indicate an increased complication rate which might negatively impact the benefit-risk balance of this procedure. In addition, standard treatment with proven efficacy might be withheld due to application of unproven methods. The use of HIPEC outside of well designed, prospective and controlled clinical trials is therefore disregarded.

AB - HIPEC is offered to patients with ovarian, fallopian tube or primary peritoneal cancer at some hospitals. Altogether, there is still no evidence that HIPEC leads to an improvement of prognosis in any gynecologic tumor, neither in primary therapy nor in treatment of relapse. The available data indicate an increased complication rate which might negatively impact the benefit-risk balance of this procedure. In addition, standard treatment with proven efficacy might be withheld due to application of unproven methods. The use of HIPEC outside of well designed, prospective and controlled clinical trials is therefore disregarded.

U2 - 10.1055/s-0032-1328320

DO - 10.1055/s-0032-1328320

M3 - SCORING: Journal article

C2 - 24771913

VL - 73

SP - 221

EP - 223

JO - GEBURTSH FRAUENHEILK

JF - GEBURTSH FRAUENHEILK

SN - 0016-5751

IS - 3

ER -